Comment on “PSMA response evaluation in follow-up PSMA-PET/CT after stereotactic ablative body radiotherapy (SABR) for oligometastases in prostate cancer”

The recently published study by Zang et al. offers valuable insight into PSMA-PET/CTbased response assessment in patients with oligometastatic prostate cancer (PCa) undergoing stereotactic ablative body radiotherapy (SABR), demonstrating an impressive 5-year local control rate of 86 % and progressiv...

Full description

Bibliographic Details
Published in:Clinical and Translational Radiation Oncology
Main Authors: Parth Aphale, Himanshu Shekhar, Shashank Dokania
Format: Article
Language:English
Published: Elsevier 2025-11-01
Subjects:
PSMA-PET/CT
SUVmax
PSMA nadir
Online Access:http://www.sciencedirect.com/science/article/pii/S2405630825001235
Description
Summary:The recently published study by Zang et al. offers valuable insight into PSMA-PET/CTbased response assessment in patients with oligometastatic prostate cancer (PCa) undergoing stereotactic ablative body radiotherapy (SABR), demonstrating an impressive 5-year local control rate of 86 % and progressive reduction in SUVmax values across follow-up intervals [1]. While the findings reinforce the utility of PSMAPET/CT as a potential biomarker for local tumor control, certain methodological and interpretive issues merit deeper consideration.
ISSN:2405-6308

Similar Items